Literature DB >> 10620138

Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome.

L H Lerner1, A A Qureshi, B V Reddy, E A Lerner.   

Abstract

Toxic epidermal necrolysis and Stevens-Johnson syndrome are severe cutaneous drug reactions of unknown mechanism. Nitric oxide can cause apoptosis and necrosis. The inducible form of nitric oxide synthase generates large amounts of nitric oxide and has been described in human skin. We propose that a large burst of nitric oxide in toxic epidermal necrolysis and Stevens-Johnson syndrome may cause the epidermal apoptosis and necrosis. Skin biopsies were taken from seven patients with actively progressing Stevens-Johnson syndrome or toxic epidermal necrolysis. Expression of inducible nitric oxide synthase was examined by reverse transcription-polymerase chain reaction and by immunoperoxidase staining for inducible nitric oxide synthase protein. Messenger RNA for inducible nitric oxide synthase was detected by reverse transcription-polymerase chain reaction and confirmed by the sequencing of polymerase chain reaction products. Strong staining for inducible nitric oxide synthase was observed in inflammatory cells in the lower epidermis and upper dermis. Diffuse, weaker staining was observed in keratinocytes. Expression of inducible nitric oxide synthase is consistent with the hypothesis that nitric oxide mediates the epidermal necrosis in toxic epidermal necrolysis and provides a potential target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620138     DOI: 10.1046/j.1523-1747.2000.00816.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.

Authors:  Riichiro Abe; Tadamichi Shimizu; Akihiko Shibaki; Hideki Nakamura; Hirokazu Watanabe; Hiroshi Shimizu
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

Review 2.  Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin.

Authors:  Sanjoy Roychowdhury; Craig K Svensson
Journal:  AAPS J       Date:  2005-12-09       Impact factor: 4.009

3.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

Review 4.  Amniotic membrane transplantation as a new therapy for the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Authors:  Elizabeth Shay; Ahmad Kheirkhah; Lingyi Liang; Hossam Sheha; Darren G Gregory; Scheffer C G Tseng
Journal:  Surv Ophthalmol       Date:  2009-08-21       Impact factor: 6.048

5.  Photocrosslinkable Gelatin Hydrogel for Epidermal Tissue Engineering.

Authors:  Xin Zhao; Qi Lang; Lara Yildirimer; Zhi Yuan Lin; Wenguo Cui; Nasim Annabi; Kee Woei Ng; Mehmet R Dokmeci; Amir M Ghaemmaghami; Ali Khademhosseini
Journal:  Adv Healthc Mater       Date:  2015-04-16       Impact factor: 9.933

Review 6.  Nitric oxide therapy for dermatologic disease.

Authors:  Brandon L Adler; Adam J Friedman
Journal:  Future Sci OA       Date:  2015-08-01

7.  Role of Oxidative and Nitrosative Stress in Pathophysiology of Toxic Epidermal Necrolysis and Stevens Johnson Syndrome-A Pilot Study.

Authors:  Dincy Peter; G Jayakumar Amirtharaj; Teena Mathew; Susanne Pulimood; Anup Ramachandran
Journal:  Indian J Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.494

8.  Nitric oxide inhibition strategies.

Authors:  Vivian Wai Chong Wong; Ethan Lerner
Journal:  Future Sci OA       Date:  2015
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.